NCT04341311View on ClinicalTrials.gov

Phase I Study of Marizomib + Panobinostat for Children With DIPG

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions
Diffuse Intrinsic Pontine GliomaPediatric Brainstem GliomaPediatric Brainstem Gliosarcoma, RecurrentPediatric CancerPediatric Brain TumorDiffuse Glioma
Interventions
DRUG

Marizomib

\- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.

DRUG

Panobinostat

\- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course

Trial Locations (2)

02115

Boston Children's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Secura Bio, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER